Compare AESI & KLRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AESI | KLRA |
|---|---|---|
| Founded | 2017 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2023 | 2026 |
| Metric | AESI | KLRA |
|---|---|---|
| Price | $5.33 | $14.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 7 |
| Target Price | $16.62 | ★ $43.00 |
| AVG Volume (30 Days) | ★ 4.7M | 988.2K |
| Earning Date | 11-02-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,095,310,000.00 | N/A |
| Revenue This Year | $1.52 | N/A |
| Revenue Next Year | $15.79 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.73 | N/A |
| 52 Week Low | $5.12 | $9.76 |
| 52 Week High | $20.13 | $23.82 |
| Indicator | AESI | KLRA |
|---|---|---|
| Relative Strength Index (RSI) | 19.11 | 60.40 |
| Support Level | N/A | $9.76 |
| Resistance Level | $14.39 | $19.15 |
| Average True Range (ATR) | 0.78 | 0.95 |
| MACD | -0.31 | 0.18 |
| Stochastic Oscillator | 6.38 | 72.47 |
Atlas Energy Solutions Inc is a provider of proppant and logistics services to the oil and natural gas industry within the Permian Basin of West Texas and New Mexico, the active oil and natural gas basin in North America. Proppant is necessary to facilitate the recovery of hydrocarbons from oil and natural gas wells. One hundred percent of its sand reserves are located in Winkler and Ward Counties, Texas, within the Permian Basin, and its operations consist of proppant production and processing facilities, including two facilities near Kermit, Texas, and a third facility near Monahans, Texas.
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.